2Owens M, Knight D, Nemeroff C. Second - generation SSRIs : Hu- man monoamine transporter binding profile of escitalopram and flu- oxetine [J]. Biol Psyehiatry,2001,50(5):345-350.
3IJadad A R,Moore R A,Carroll D,et al. Assessing the quality of re- ports of randomized clinical trials:Is blinding necessary? [J] Control Clin Trials, 1.996,17(1 ) : 1-12.
5Mohamed S,Osatuke K, Aslam M ,et aL Escitalopram for comorbid depression and anxiety in elderly patients: A 12-week,open-la- bel, flexible - dose, pilot trial [J]. Am J Geriatr Pharmaeother, 2006,4(3) : 201-209.
6Kasper S, Swart H, Andersen H. Eseitalopram in the treatment of depressed elderly patients [J]. Am J Geriatr Psychiatry, 2005, 13 (10) :884-891.
7Alejandro R. Jadad,R.Andrew Moore,Dawn Carroll,Crispin Jenkinson,D.John M. Reynolds,David J. Gavaghan,Henry J. McQuay.Assessing the quality of reports of randomized clinical trials: Is blinding necessary?[J]. Controlled Clinical Trials . 1996 (1)
8Somaia Mohamed,Katerine Osatuke,Muhammed Aslam,John Kasckow.Escitalopram for comorbid depression and anxiety in elderly patients: A 12-week, open-label, flexible-dose, pilot trial[J].American Journal of Geriatric Pharmacotherapy.2006(3)
9Siegfried Kasper,Hans de Swart,Henning Friis Andersen.Escitalopram in the Treatment of Depressed Elderly Patients[J].American Journal of Geriatric Psychiatry.2005(10)
